Monitor for the EFFECT notice (IPO pricing and closing) and any updates on the Moltex Asset Acquisition. The stock will likely be highly volatile post-IPO given the speculative, pre-revenue nature of the business. Watch for subsequent capital raises and regulatory milestones (CNSC VDR, NRC engagement) as key catalysts.
Executive Summary
Nuclea Energy Inc. filed Amendment No. 4 to its F-1 registration statement for an IPO of 5,555,556 common shares at an estimated $8-$10 per share (midpoint $9), with a concurrent resale of 2,817,294 shares by selling shareholders. The company is a pre-revenue, development-stage Canadian nuclear microreactor developer with no revenue since inception, cumulative net losses of $2.2M as of Dec 31, 2025, and a going concern qualification. Net proceeds of ~$45.5M will fund an 18-month development roadmap, but the company faces massive technical, regulatory, and capital risks with a need for hundreds of millions more in future funding.
Key Financial Metrics
Key Facts
- Pre-revenue since inception (Aug 24, 2023); no revenue ever generated
- Net loss of $1,945,868 for H1 FY2026 (6 months ended Dec 31, 2025), vs $83,657 loss in prior-year period
- Accumulated deficit of $2,198,532 as of Dec 31, 2025
- Cash of $3,230,952 as of Dec 31, 2025; going concern qualification in financial statements
- IPO of 5,555,556 common shares at estimated $8-$10 per share (midpoint $9); net proceeds ~$45.5M
- Concurrent resale of 2,817,294 shares by selling shareholders; company receives no proceeds from resale
- Moltex Asset Acquisition (distressed IP purchase for ~£6.2M) remains pending; exclusivity extended to July 8, 2026
- CEO Josef Freundorfer's employment agreement amended June 16, 2026 to clarify $100M equity financing bonus condition excludes IPO proceeds
- 180-day lock-up agreements for all directors, officers, and 3%+ shareholders; leak-out provisions for certain holders
- Immediate dilution of $7.74 per share for new investors at midpoint offering price
Financial Impact
IPO raises ~$45.5M net proceeds; company needs potentially hundreds of millions more for development through 2030-2031 commercialization target
Risk Factors
- Pre-revenue with no guarantee of commercialization; Morpheus reactor is first-of-a-kind and unvalidated
- Massive future capital needs (potentially hundreds of millions) beyond IPO proceeds
- Regulatory approval from CNSC and NRC is uncertain and could take years
- HALEU fuel supply chain does not yet exist commercially
- Moltex Asset Acquisition may not close; distressed assets may not yield anticipated benefits
- Concentration of control by two 25.4% shareholders post-IPO (Sanghera and Gunda)
- Foreign private issuer status limits disclosure requirements
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-069326 |
| Document: ea027004317ex10-11.htm | 0001213900-26-069326 |
| Document: ea027004317ex23-1.htm | 0001213900-26-069326 |
| Document: 0001213900-26-069326-index-headers.html | 0001213900-26-069326 |
| Document: 0001213900-26-069326-index.html | 0001213900-26-069326 |
| Document: 0001213900-26-069326.txt | 0001213900-26-069326 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 16w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 29, 2026 17w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 16, 2026 19w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 9, 2026 20w ago | F-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers